Ex Comp/Streamer
Joined January 2020
- Tweets3.6K
- Following49
- Followers307
- Likes4.4K
Intense retweeted
This girl decided to do a TikTok live without wearing hijab. Her parents saw it, so they burst into the room and beat her up.
This is Islam.
Intense retweeted
Stop what you're doing, and watch this. I exposed the islamic takeover of Birmingham and it's much more insane than you can imagine.
"So you think everyone who cheats in the UK should be killed?"
"They shouldn't cheat."
They want sharia law and reveal their plan to me on how they intend to implement it. I went into the mosque where they teach sharia lectures including how to stone your wife to death and tax funded field trips from public schools are sent to this mosque, more than 40 in fact. This is part of a much larger report that is released on my YouTube.
Intense retweeted
It sounds like a horror movie but it's hordes of fake African asylum seekers who want to invade Spain in Ceuta.
Intense retweeted
The LARGEST human ivermectin cancer study EVER conducted found 84% of cancer patients declared COMPLETE REMISSION, TUMOR SHRINKAGE, or HALTED TUMOR GROWTH.
Our study is now PEER-REVIEWED and PUBLISHED by the International Institute of Anticancer Research.
The tide is turning.
BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal
84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.
Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.
The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.
Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.
At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)
Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.
Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.
This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.
With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.
In the meantime, many cancer patients are exercising their right to try.
@twc_health @McCulloughFund @IIAR_Journals @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson
Intense retweeted
Andrew Tate talks to Nick Fuentes about his position on JD Vance for 2028 Presidency:
